|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from (used in) operating activities: | |||||
| Net income | |||||
| Less: Loss from discontinued operations, net of tax | |||||
| Income from continuing operations | |||||
| Adjustments to reconcile income from continuing operations to net cash from (used in) operating activities | |||||
| Loss on divestiture of asbestos-related assets and liabilities | |||||
| Special charges, net | |||||
| (Gain) loss on change in fair value of equity security | |||||
| (Gain) loss on change in value of equity security | |||||
| Loss on change in value of equity security | |||||
| Loss on amendment/refinancing of senior credit agreement | |||||
| Amortization of compensation expense related to acquisition (Refer to Note 4) | |||||
| Impairment of intangible assets | |||||
| Deferred and other income taxes | |||||
| Depreciation and amortization | |||||
| Pension and other employee benefits | |||||
| Long-term incentive compensation | |||||
| Other, net, including allowance for doubtful accounts | |||||
| Contribution to divest asbestos-related assets and liabilities | |||||
| Changes in operating assets and liabilities, net of effects from acquisitions and divestitures: | |||||
| Accounts receivable and other assets | |||||
| Contribution related to employee retention agreements from acquisition (Refer to Note 4) | |||||
| Inventories | |||||
| Accounts payable, accrued expenses and other | |||||
| Cash spending on restructuring actions | |||||
| Net cash from continuing operations | |||||
| Net cash used in discontinued operations | |||||
| Net cash from operating activities | |||||
| Cash flows from (used in) investing activities: | |||||
| Proceeds/borrowings (repayments) related to company-owned life insurance policies, net | |||||
| Proceeds from asset sales and other | |||||
| Business acquisitions, net of cash acquired | |||||
| Capital expenditures | |||||
| Net cash used in continuing operations | |||||
| Net cash used in discontinued operations | |||||
| Net cash used in investing activities | |||||
| Cash flows from (used in) financing activities: | |||||
| Borrowings under senior credit facilities | |||||
| Repayments under senior credit facilities | |||||
| Borrowings under trade receivables agreement | |||||
| Repayments under trade receivables agreement | |||||
| Net borrowings (repayments) under other financing arrangements | |||||
| Payment of contingent consideration | |||||
| Minimum withholdings paid on behalf of employees for net share settlements, net of proceeds from the exercise of employee stock options and other | |||||
| Repurchases of common stock | |||||
| Proceeds of issuance of common stock in underwritten public offering, net of offering costs of $23.9 | |||||
| Financing fees paid | |||||
| Net cash from continuing operations | |||||
| Net cash from (used in) discontinued operations | |||||
| Net cash from financing activities | |||||
| Change in cash and equivalents due to changes in foreign currency exchange rates | |||||
| Net change in cash and equivalents | |||||
| Consolidated cash and equivalents, beginning of period | |||||
| Consolidated cash and equivalents, end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Interest paid | |||||
| Income tax payments, net | |||||
| Non-cash investing and financing activity: | |||||
| Debt assumed | |||||
Loading...